about
ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2Minimal residual disease-directed therapy in acute myeloid leukemiaTargeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualizationAKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicinGemcitabine-associated hemolytic-uremic syndrome.Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion.Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II studyMcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia.High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology groupPretargeted radioimmunotherapy for hematologic and other malignanciesOutpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemiaHigh expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignmentCancer risk associated with long-term use of acetaminophen in the prospective VITamins and lifestyle (VITAL) study.Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology GroupEffect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinHeight as an explanatory factor for sex differences in human cancer.High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Associations between allergies and risk of hematologic malignancies: results from the VITamins and lifestyle cohort studyThe past and future of CD33 as therapeutic target in acute myeloid leukemia.Update on antigen-specific immunotherapy of acute myeloid leukemia.Minimal residual disease in acute myeloid leukemia--current status and future perspectives.Assessment of digital clubbing in medical inpatients by digital photography and computerized analysis.Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptor.Quality of life from the perspective of the patient with acute myeloid leukemia.Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.Functional expression of the CD163 scavenger receptor on acute myeloid leukemia cells of monocytic lineage.Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women's Health Initiative.How Do Pretransplantation Peripheral Blood Counts Inform Us about Post-Transplantation Outcomes in Acute Myeloid Leukemia?A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.Myeloid sarcoma of the heart.The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapyEffect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia.
P50
Q24298136-64FF1A29-5328-411A-99BC-2F670E7D7841Q26864644-7B49AA15-C6FF-485A-8534-3D40BCDC218BQ28476825-48DD3F71-AF5F-4988-BB44-9FB55C433AFFQ28484890-5F73B5CA-3F8F-4A64-B1FA-56B0F765E766Q33344441-0E20AF84-A0D6-4F3E-8556-FD09361DEF25Q33349375-54F5FA2C-9D87-4F1A-8C67-050FA1911BC3Q33558088-53F671C0-0BB0-489D-A3D2-C5C4075EED95Q33925386-242F95B7-A238-40C1-B4DB-6305FCD71323Q33990843-4B971FC2-A46D-42B4-8BEE-97D41D99B49FQ34113941-93CF3E36-4D99-42FD-9067-FA2AA85A04FCQ34418965-D1989BE2-15A6-4404-B93C-320944060C30Q34845224-B71B386D-048D-4BB2-9D31-356C27A3EFC1Q35054435-A7E7E15A-9F86-4FCF-B6CD-BB048EC771F1Q35565648-32C4AFCA-C510-4FBB-A9B6-E99621613F91Q35613565-82DF29AF-E867-439F-A257-0A95A42BB8F2Q35862717-10C69786-048E-4114-B7EC-339E20F08ED9Q36069041-C5860B95-F84B-433D-9143-82F0F8CB898CQ36406975-BD88F4C9-70DA-4CF5-B7CB-DC1EFC05F291Q36716744-E2562296-EA20-42BF-AC58-732A1BEE9D79Q36932014-3BA73A65-B395-4025-96CA-14C78C6F38FEQ36942433-3B961945-2BA9-4FFD-A9F4-BE48DE26A534Q37131914-B96E8159-5711-40F5-95EC-59FE90A4EB01Q37512086-3B39BCEC-5E8C-4224-9A5A-95FCDD3E6575Q37727195-60A0C785-F79A-40DD-A331-EDD54FD5F0D4Q38210228-A557E3B1-FDF6-49DD-95E1-F2A27FF6FAD6Q38432103-A4E69604-3CBA-4C23-9A57-A76258431E47Q38494659-9F56EB89-7868-447C-9B62-8F2F74EADFFFQ39604552-0D26842D-9213-42D9-8374-7E862B1E8A16Q40038804-EA8BF509-429B-42E6-AFD3-71AC6976BD52Q40053499-8F546346-0CA1-404E-AAC8-C621CE19B961Q40055082-118EC54C-1B8F-4E82-8AED-9C3A0000BF45Q40337699-9BA0FA05-C03C-4ADA-8E3C-4ACACDC74150Q40509797-183C15F0-4760-4FE6-8FBF-F745E1DB4A7BQ41320689-683D2206-64EF-44CD-A482-D18CA9C43047Q41444798-546643EE-288A-485E-ACD5-1D6F0FCC98C8Q41722063-8623A5E3-6B58-446B-B9EC-757DA7C86C0CQ41872131-01C3CE08-24D0-42E2-A3AF-36ADE5FC4D93Q42152527-BA2BEBB9-E63C-4367-81F8-91BDFFB5006BQ42358970-FC5B0F19-5A6B-4888-A887-6359618D2B26Q42384543-EAC8580E-0B76-4F75-8C6B-33144AF66835
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roland B Walter
@ast
Roland B Walter
@en
Roland B Walter
@es
Roland B Walter
@nl
Roland B Walter
@sl
type
label
Roland B Walter
@ast
Roland B Walter
@en
Roland B Walter
@es
Roland B Walter
@nl
Roland B Walter
@sl
prefLabel
Roland B Walter
@ast
Roland B Walter
@en
Roland B Walter
@es
Roland B Walter
@nl
Roland B Walter
@sl
P1053
C-1064-2008
P106
P21
P31
P3829
P496
0000-0002-9268-3341